Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1475-2867

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity ; volume:9 ; number:1 ; day:17 ; month:2 ; year:2009 ; pages:1-13 ; date:12.2009
Cancer cell international ; 9, Heft 1 (17.2.2009), 1-13, 12.2009

Creator: Freeburg, Elizabeth M.

Contributor: Goyeneche, Alicia A.
Seidel, Erin E.
Telleria, Carlos M.
SpringerLink (Online service)

DOI: 10.1186/1475-2867-9-4

URN: urn:nbn:de:1111-2016073015562

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:57 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Freeburg, Elizabeth M.
Goyeneche, Alicia A.
Seidel, Erin E.
Telleria, Carlos M.
SpringerLink (Online service)

Other Objects (12)

Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity

FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells

Cysteine allows ovarian cancer cells to adapt to hypoxia and to escape from carboplatin cytotoxicity

Cytotoxicity of some synthetic bis(arylidene) derivatives of cyclic ketones towards cisplatin-resistant human ovarian carcinoma cells

The ferroptosis inducer erastin irreversibly inhibits system xc− and synergizes with cisplatin to increase cisplatin’s cytotoxicity in cancer cells

Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin

CARD9 contributes to ovarian cancer cell proliferation, cycle arrest, and cisplatin sensitivity

Non-phosphorylatable PEA-15 sensitises SKOV-3 ovarian cancer cells to cisplatin

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib

Role of Purinergic Ligands to Enhance Cisplatin Sensitivity in Ovarian Cancer Cells

HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells

Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity

FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells

Cysteine allows ovarian cancer cells to adapt to hypoxia and to escape from carboplatin cytotoxicity

Cytotoxicity of some synthetic bis(arylidene) derivatives of cyclic ketones towards cisplatin-resistant human ovarian carcinoma cells

The ferroptosis inducer erastin irreversibly inhibits system xc− and synergizes with cisplatin to increase cisplatin’s cytotoxicity in cancer cells

Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin

CARD9 contributes to ovarian cancer cell proliferation, cycle arrest, and cisplatin sensitivity

Non-phosphorylatable PEA-15 sensitises SKOV-3 ovarian cancer cells to cisplatin

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib

Role of Purinergic Ligands to Enhance Cisplatin Sensitivity in Ovarian Cancer Cells

HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells

Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity

FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells

Cysteine allows ovarian cancer cells to adapt to hypoxia and to escape from carboplatin cytotoxicity

Cytotoxicity of some synthetic bis(arylidene) derivatives of cyclic ketones towards cisplatin-resistant human ovarian carcinoma cells

The ferroptosis inducer erastin irreversibly inhibits system xc− and synergizes with cisplatin to increase cisplatin’s cytotoxicity in cancer cells

Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin

CARD9 contributes to ovarian cancer cell proliferation, cycle arrest, and cisplatin sensitivity

Non-phosphorylatable PEA-15 sensitises SKOV-3 ovarian cancer cells to cisplatin

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib

Role of Purinergic Ligands to Enhance Cisplatin Sensitivity in Ovarian Cancer Cells

HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity

FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells

Cysteine allows ovarian cancer cells to adapt to hypoxia and to escape from carboplatin cytotoxicity

Cytotoxicity of some synthetic bis(arylidene) derivatives of cyclic ketones towards cisplatin-resistant human ovarian carcinoma cells

The ferroptosis inducer erastin irreversibly inhibits system xc− and synergizes with cisplatin to increase cisplatin’s cytotoxicity in cancer cells

Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin

CARD9 contributes to ovarian cancer cell proliferation, cycle arrest, and cisplatin sensitivity

Non-phosphorylatable PEA-15 sensitises SKOV-3 ovarian cancer cells to cisplatin

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib

Role of Purinergic Ligands to Enhance Cisplatin Sensitivity in Ovarian Cancer Cells

HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells

Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity

FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells

Cysteine allows ovarian cancer cells to adapt to hypoxia and to escape from carboplatin cytotoxicity

Cytotoxicity of some synthetic bis(arylidene) derivatives of cyclic ketones towards cisplatin-resistant human ovarian carcinoma cells

The ferroptosis inducer erastin irreversibly inhibits system xc− and synergizes with cisplatin to increase cisplatin’s cytotoxicity in cancer cells

Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin

CARD9 contributes to ovarian cancer cell proliferation, cycle arrest, and cisplatin sensitivity

Non-phosphorylatable PEA-15 sensitises SKOV-3 ovarian cancer cells to cisplatin

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib

Role of Purinergic Ligands to Enhance Cisplatin Sensitivity in Ovarian Cancer Cells

HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells

Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity

FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells

Cysteine allows ovarian cancer cells to adapt to hypoxia and to escape from carboplatin cytotoxicity

Cytotoxicity of some synthetic bis(arylidene) derivatives of cyclic ketones towards cisplatin-resistant human ovarian carcinoma cells

The ferroptosis inducer erastin irreversibly inhibits system xc− and synergizes with cisplatin to increase cisplatin’s cytotoxicity in cancer cells

Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin

CARD9 contributes to ovarian cancer cell proliferation, cycle arrest, and cisplatin sensitivity

Non-phosphorylatable PEA-15 sensitises SKOV-3 ovarian cancer cells to cisplatin

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib

Role of Purinergic Ligands to Enhance Cisplatin Sensitivity in Ovarian Cancer Cells

HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells

Related objects

Reset password